Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf your weight loss injections are not working as you expected, you are not alone, and there are usually identifiable reasons. These medicines (tirzepatide (Mounjaro) and semaglutide (Wegovy)) reduce appetite and slow how quickly the stomach empties, but they work within a biological context that varies from person to person. A flat week on the scales does not mean the treatment has failed. The decision you actually face is whether the problem sits with the dose, the duration, something happening alongside treatment, or whether a clinical conversation is overdue. These are prescription-only medicines that require ongoing assessment; working out which factor applies to you is exactly what a prescriber is there for.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The single most common reason people feel their injections have stopped working is timing. Both tirzepatide and semaglutide follow a dose-escalation schedule that takes months to reach the therapeutic range where the strongest appetite effects are felt. The opening weeks are about letting your body adjust, not about maximising results. If you are still at the lower end of the dose ladder, a plateau is expected rather than worrying.
A different pattern emerges once someone has been stable on a maintenance dose for several months: weight loss that was progressing slows, then stops. This is also normal physiology. The body defends its new weight with the same hormonal stubbornness it used to defend the old one. Research published in the New England Journal of Medicine on SURMOUNT-1 showed that tirzepatide participants continued losing weight well past the twelve-week mark, with the steepest reductions typically between months three and nine. Expecting a straight line from week one is the single fastest route to unnecessary disappointment.
The practical question is straightforward: how long have you been on your current dose, and have you reached the dose your prescriber expects to be therapeutic for you? If the answer is no to either, time and titration are the most likely solution. If you are wondering whether the medicine is doing anything at all, our page on how weight loss injections work explains the underlying mechanisms and what to expect as your dose increases. You can also read more about how the treatment trajectory typically unfolds on our page about when weight loss injections start working.
A prescription pen sitting in your fridge door does not work in isolation. Several factors consistently reduce the real-world effect of GLP-1 and dual-agonist medicines, and identifying which applies to you is the productive step.
Caloric compensation: These medicines reduce hunger, but they do not make it impossible to eat past a comfortable point. Ultra-processed foods, liquid calories and grazing in the evening can collectively offset the appetite suppression, sometimes without the person noticing. The NHS guidance on tirzepatide on the NHS medicines pages is clear that treatment is intended alongside a reduced-calorie diet and increased activity, not instead of those things.
Sleep and stress: Cortisol and sleep deprivation both raise hunger hormones independently of the medicine. People who resolve a significant stressor or improve their sleep sometimes find the injection's effects become noticeably stronger, without any dose change.
Other medicines: Some antidepressants, corticosteroids and antipsychotics promote weight gain through separate mechanisms that GLP-1 medicines cannot fully counteract. This is not a reason to stop either medicine without speaking to your prescriber first, but it is worth raising.
Injection technique: Subcutaneous injection into the right tissue depth matters. Injecting too shallow (into skin rather than fat) reduces absorption. Rotating the injection site (abdomen, thigh, upper arm) each week, and ensuring the pen has been at room temperature for the recommended period before use, both support consistent delivery. Our guide to taking weight loss injections covers technique in more detail.
There is a meaningful difference between a natural lull and a true treatment plateau. A true plateau, for NICE's purposes, is defined as less than five percent weight loss after six months at the highest dose the person can tolerate. At that point, the guidance suggests formally reviewing whether the medicine remains appropriate.
Short of that threshold, most stalls have a cause that a prescriber can identify and address, whether that is dose adjustment, a review of concurrent medicines, or a more structured look at what is happening around the treatment. This is precisely why these medicines require clinical oversight rather than self-management. Every repeat order at our pharmacy involves a clinical re-review; it is not automatic. If something has shifted since your last assessment, that review is the place to raise it.
It is also worth knowing what a genuine response looks like across the full population. The NICE appraisal of tirzepatide (TA1026) drew on evidence showing average reductions of around twenty percent at the highest dose over seventy-two weeks. Most of that loss did not happen in month one. For context on how the injectable options compare, our overview of weight loss injections sets out what each medicine has been shown to do in trials.
Start by ruling out the straightforward things. Check your injection technique, look honestly at your eating pattern over the past two to three weeks, and consider whether anything has changed, sleep, stress, a new medicine. If nothing has changed and you have been on the same dose for more than eight to ten weeks without any movement, our page on why weight loss injections stop working covers the most common clinical reasons in detail, and is a useful starting point before you contact your prescriber.
Contact your prescriber's team. Do not simply stop the medicine without guidance, discontinuation affects appetite hormones in the other direction, and any decision about switching, increasing dose, or stopping should be made with clinical input. If you are currently between providers or considering a fresh assessment, our FAQs explain how the consultation process works. Alternatively, you can explore the full range of weight loss treatment options to understand what a fresh clinical review might consider.
One thing worth knowing: when a new patient joins a service like ours, their pen arrives by tracked DPD delivery the next working day, in plain, unbranded packaging. That part of the process is sorted. If you are also weighing up which medicine to start with, our guide to the fastest working weight loss injections sets out how the options compare on speed of effect. The part that actually determines results is the clinical conversation that precedes it.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.